The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus

Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0096421. doi: 10.1128/AAC.00964-21. Epub 2021 Sep 20.

Abstract

The antituberculosis drug telacebec is ineffective against Mycobacterium abscessus. A recent study suggested that TB47, a telacebec analogue, potentiated the efficacy of clofazimine against M. abscessus. Here, we report that TB47 not only is ineffective against M. abscessus in vitro but also does not potentiate the activity of clofazimine.

Keywords: Q203; cytochrome bcc:aa3; nontuberculous mycobacteria; oxidative phosphorylation; terminal oxidase; tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Antitubercular Agents / pharmacology
  • Clofazimine / pharmacology
  • Humans
  • Imidazoles
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous*
  • Mycobacterium abscessus*
  • Piperidines
  • Pyridines

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Imidazoles
  • Piperidines
  • Pyridines
  • telacebec
  • Clofazimine